Figure 1.

Panel of anti-SARS-CoV-2 mAbs

Hybridoma supernatants were assayed for neutralization of SARS-CoV-2 by FRNT, cross-reactivity to SARS-CoV-1 spike protein, and ability to inhibit SARS-CoV-2 spike protein binding to hACE2 or a panel of reference human mAbs through competition ELISA. mAbs are grouped by reference mAb competition properties. Data represent the mean (or geometric mean for EC₅₀ values) from two to four experiments. Hybridomas were produced from splenocytes of mice that received three immunizations (once with RBD and then twice with spike) prior to a final pre-fusion boost with RBD or spike, as indicated in the “Final Boost” column.